AR064376A1 - Imidazoles sustituios como ligandos de taar, un proceso para su obtencion, y su uso en la preparacion de un medicamento para el tratamiento de enfermedades asociadas a la desregulacion de aminas traza. - Google Patents

Imidazoles sustituios como ligandos de taar, un proceso para su obtencion, y su uso en la preparacion de un medicamento para el tratamiento de enfermedades asociadas a la desregulacion de aminas traza.

Info

Publication number
AR064376A1
AR064376A1 ARP070105650A ARP070105650A AR064376A1 AR 064376 A1 AR064376 A1 AR 064376A1 AR P070105650 A ARP070105650 A AR P070105650A AR P070105650 A ARP070105650 A AR P070105650A AR 064376 A1 AR064376 A1 AR 064376A1
Authority
AR
Argentina
Prior art keywords
formula
compound
defined above
lower alkyl
meaning defined
Prior art date
Application number
ARP070105650A
Other languages
English (en)
Inventor
Guido Galley
Zbinden Katrin Groebke
Roger Nocross
Henri Stalder
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR064376A1 publication Critical patent/AR064376A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de la formula (1) en la que R es H, alquilo inferior o amino; X-R1 es -CH2-, -CH(alcoxi inferior)- o -CH(OH)- y Y-R2 es -CH2-, -CH(alquilo inferior)-, -CH(alcoxi inferior)-, -O-, -S-, -S(O)-, -S(O)2-, -CH(fenil)- o -C(alquilo inferior)2-; o X-R1 es NH- y Y-R2 es -CH2, -CH(alquilo inferior)-, -CH(alcoxi inferior)-, -CH(fenil)- o -C(alquilo inferior)2-. Reivindicacion 10: Un proceso de obtencion de los compuestos de la formula (1), dicho proceso consiste en: a) desproteger un compuesto de la formula (2) para obtener un compuesto de la formula (1) en las que las definiciones son las que se han indicado antes o b) hidrogenar un compuesto de formula (5) para obtener un compuesto de la formula (3) y desprotegerlo con arreglo al paso a) para obtener un compuesto de la formula (4) en las que Ar tiene el significado definido anteriormente y R2 es H, alquilo inferior o alcoxi inferior, o c) alquilar un compuesto de la formula (9) para obtener un compuesto de la formula (6) y desprotegerlo con arreglo al paso a) para obtener un compuesto de la formula (7) en las que Ar tiene el significado definido anteriormente; o d) hacer reaccionar un compuesto de la formula (11) y un compuesto de la formula ArOH para obtener un compuesto de la formula (8) y desprotegerlo con arreglo al paso a) para obtener un compuesto de la formula (10) en las que las definiciones son las descritas anteriormente o e) hacer reaccionar un compuesto de la formula (12) con acetonitrilo para obtener un compuesto de formula (13) y eliminar el grupo hidroxi para obtener un compuesto de la formula (14) en la que Ar tiene el significado definido anteriormente, o f) hacer reaccionar un compuesto de la formula (15) con un compuesto de formula (16) para obtener un compuesto de la formula (17) y desprotegerlo para obtener un compuesto de la formula (18) en la que R es alquilo inferior y Ar tiene el significado definido anteriormente, o g) hacer reaccionar un compuesto de la formula (11) y un compuesto de la formula ArSH para obtener un compuesto de la formula (19) y desprotegerlo con arreglo al paso a) para obtener un compuesto de la formula (20), en la que Ar tiene el significado definido anteriormente, o h) oxidar un compuesto de la formula (19) para obtener compuesto de las formulas (21), (22) y desprotegerlos con arreglo al paso a) para obtener compuestos de las formulas (23), (24), en las que Ar tiene el significado definido anteriormente; o i) reducir un compuesto de la formula (25) para obtener un compuesto de la formula (26) y desprotegerlo con arreglo al paso a) para obtener compuestos de la formula (27) en la que Ar tiene el significado definido anteriormente y PG es un grupo protector habitual de N; y, si se desea, convertir los compuestos obtenidos en sales de adicion de ácido farmacéuticamente aceptables.
ARP070105650A 2006-12-18 2007-12-17 Imidazoles sustituios como ligandos de taar, un proceso para su obtencion, y su uso en la preparacion de un medicamento para el tratamiento de enfermedades asociadas a la desregulacion de aminas traza. AR064376A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06126307 2006-12-18

Publications (1)

Publication Number Publication Date
AR064376A1 true AR064376A1 (es) 2009-04-01

Family

ID=39153757

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105650A AR064376A1 (es) 2006-12-18 2007-12-17 Imidazoles sustituios como ligandos de taar, un proceso para su obtencion, y su uso en la preparacion de un medicamento para el tratamiento de enfermedades asociadas a la desregulacion de aminas traza.

Country Status (18)

Country Link
US (3) US20080146523A1 (es)
EP (1) EP2094668A2 (es)
JP (1) JP5175297B2 (es)
KR (1) KR101188992B1 (es)
CN (1) CN101578271B (es)
AR (1) AR064376A1 (es)
AU (1) AU2007336351A1 (es)
BR (1) BRPI0721291A2 (es)
CA (1) CA2671838A1 (es)
CL (1) CL2007003653A1 (es)
IL (1) IL198878A0 (es)
MX (1) MX2009006215A (es)
NO (1) NO20091936L (es)
PE (1) PE20081386A1 (es)
RU (1) RU2465269C2 (es)
TW (1) TWI345467B (es)
WO (1) WO2008074679A2 (es)
ZA (1) ZA200903841B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008098857A1 (en) 2007-02-15 2008-08-21 F. Hoffmann-La Roche Ag 2-aminooxazolines as taar1 ligands
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012078817A1 (en) 2010-12-08 2012-06-14 Vanderbilt University Bicyclic pyrazole compounds as allosteric modulators of mglur5 receptors
WO2012125732A1 (en) * 2011-03-15 2012-09-20 Vanderbilt University Substituted imadazapyrinidin-5(6h)-ones as allosteric modulators of mglur5 receptors
US8865725B2 (en) 2011-03-15 2014-10-21 Vanderbilt University Substituted imidazopyrimidin-5(6H)-ones as allosteric modulators of MGLUR5 receptors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN103910658B (zh) * 2013-12-23 2016-08-17 宁夏大学 一种硫醚氧化成砜的方法
WO2015165085A1 (en) 2014-04-30 2015-11-05 F.Hoffmann-La Roche Ag Morpholin-pyridine derivatives

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2731471A (en) * 1956-01-17 Nxg hi
US2161938A (en) * 1934-07-31 1939-06-13 Soc Of Chemical Ind Imidazolines
US2457047A (en) * 1946-02-13 1948-12-21 Monsanto Chemicals 2-(2'-thenyl)-4, 5-dihydroimidazoles and process for making the same
GB725514A (en) 1952-08-28 1955-03-02 Abbott Lab Improvements in or relating to 4(5)-aryloxymethylimidazoles and their preparation
US2778836A (en) * 1954-04-02 1957-01-22 Union Chimique Belge Sa Substituted 2-methyl-delta2 imidazolines
US2744909A (en) * 1955-06-27 1956-05-08 Bristol Lab Inc 2-(ortho-phenylbenzyl) imidazoline and acid addition salts
US2744910A (en) * 1955-06-27 1956-05-08 Bristol Lab Inc 2-(ortho-benzylbenzyl)-imidazoline and acid addition salts
US2919274A (en) * 1957-09-17 1959-12-29 Sahyun Melville Amidines
GB877306A (en) 1958-04-21 1961-09-13 Pfizer & Co C Halogenated derivatives of tetrahydro-1-naphthyl cyclic amidines
DE1121054B (de) * 1960-11-23 1962-01-04 Merck Ag E Verfahren zur Herstellung eines neuen Imidazolinderivates und dessen Saeureadditionssalzen
US3202660A (en) 1961-10-09 1965-08-24 Boehringer Sohn Ingelheim Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes
DE1150180B (de) * 1962-04-12 1963-06-12 Merck Ag E Mittel zur Vorbehandlung der Haut fuer die Rasur
ES323985A1 (es) 1966-02-26 1966-12-16 Blade Pique Juan Procedimiento para la obtenciën de derivados del imidazol
US3377247A (en) * 1967-04-28 1968-04-09 Dow Chemical Co Antidepressant method
US3586695A (en) * 1968-01-26 1971-06-22 Dow Chemical Co Substituted imidazolinyl indoles
BE754820R (fr) * 1969-08-13 1971-02-15 Schering Ag Nouveaux derives de pyrimidine, leurs procedes de preparation et leurs
US3818094A (en) * 1969-08-28 1974-06-18 Boehringer Sohn Ingelheim Hypotensive pharmaceutical compositions containing certain 2-anilino-1,3-diazacyclopentenes-(2)
US3622579A (en) * 1969-08-28 1971-11-23 Boehringer Sohn Ingelheim Derivatives of 2-anilino-1,3-diazacyclopentene-(2)
US3660423A (en) * 1970-02-13 1972-05-02 Dow Chemical Co 2-(substituted benzyl)methyl-2-imidazolines
GB1333471A (en) * 1971-01-27 1973-10-10 Labaz Imidazoline derivatives and process for preparing the same
JPS49134834A (es) * 1973-05-07 1974-12-25
US4125620A (en) * 1974-10-01 1978-11-14 Boehringer Ingelheim Gmbh 2-[(2',6'-Disubstituted-phenyl)-imino]-imidazolidines and salts thereof
US3992403A (en) * 1975-05-30 1976-11-16 Schering Corporation 2-Imidazolines and their use as hypoglycemic agents
GB1538097A (en) * 1976-01-26 1979-01-10 Lafon Labor Substituted phenyl-amidines
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
AU518569B2 (en) 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
GB2069481B (en) * 1980-02-13 1983-07-27 Farmos Oy Substituted imidazole derivatives
GB2092569B (en) * 1981-02-05 1984-09-19 Farmos Oy Substituted imidazole derivatives and their preparation and use
GB2101114B (en) * 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
US4540705A (en) 1983-03-14 1985-09-10 Sterling Drug Inc. Antidepressant imidazolines and related compounds
EP0166937B1 (en) 1984-06-06 1991-08-28 Abbott Laboratories Adrenergic compounds
US4605661A (en) * 1984-06-18 1986-08-12 Eli Lilly And Company Aromastase inhibiting α,α-diarylimidazole-4(5)-propionitriles, α,α-diarylimidazole-4(5)-propionamides, and 4(5)-(2,2-diarylethyl)imidazoles
LU85747A1 (fr) * 1985-01-28 1986-08-04 Continental Pharma Derives d'imidazole leur preparation et utilisation ainsi que les compositions pharmaceutiques contenant des derives
US4665095A (en) * 1985-12-11 1987-05-12 Abbott Laboratories Use of 2-[(3,5-dihalo-4-aminobenzyl)]imidazolines to stimulate alpha-1 adrenergic receptors and to treat nasal congestion
JPS62265270A (ja) * 1986-05-13 1987-11-18 Zeria Shinyaku Kogyo Kk 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
JPH0774205B2 (ja) * 1986-12-04 1995-08-09 三井石油化学工業株式会社 新規イミダゾ−ル誘導体
GB2215206B (en) 1988-02-29 1991-07-03 Farmos Oy 4-substituted imidazole derivatives useful in perioperative care
GB2229719B (en) * 1989-03-30 1992-04-29 Farmos Oy Novel aromatase inhibiting 4(5)-imidazoles
FI894911A0 (fi) 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
FR2669030B1 (fr) * 1990-11-14 1992-12-31 Adir Nouveaux derives d'imidazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
AU707843B2 (en) 1993-10-13 1999-07-22 Concordia Pharmaceuticals Inc. Extended release clonidine formulation
ATE234290T1 (de) * 1993-11-15 2003-03-15 Schering Corp Phenylalkyl-imidazole als h3-rezeptor- antagonisten
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
US5610174A (en) * 1995-06-02 1997-03-11 Synaptic Pharmaceutical Corporation Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
US5969137A (en) 1996-09-19 1999-10-19 Virginia Commonwealth University Benzylamidine derivatives with serotonin receptor binding activity
NO980546L (no) 1997-02-11 1998-08-12 Lilly Co Eli Farmas°ytiske midler
US5866579A (en) * 1997-04-11 1999-02-02 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
NZ504667A (en) 1997-12-04 2003-03-28 Allergan Sales Inc Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
DE69814012T2 (de) 1997-12-19 2004-04-01 Eli Lilly And Co., Indianapolis Hypoglykàmische imidazoline derivate
ATE293102T1 (de) * 1998-04-23 2005-04-15 Takeda Pharmaceutical Naphthalene derivate ,ihre herstellung und verwendung
CA2246027A1 (en) 1998-08-27 2000-02-27 Virginia Commonwealth University Benzylamidine derivatives with serotonin receptor binding activity
EP1013243A3 (en) 1998-12-21 2002-10-16 Benoist Girard Sas Femoral component for use in replacement hip joint
PE20010781A1 (es) 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
FI20000073A0 (fi) 2000-01-14 2000-01-14 Orion Yhtymae Oy Uusia imidatsolijohdannaisia
JP2001302643A (ja) 2000-04-21 2001-10-31 Suntory Ltd 環状アミジン化合物
US6495464B1 (en) 2000-06-30 2002-12-17 Lam Research Corporation Method and apparatus for fixed abrasive substrate preparation and use in a cluster CMP tool
EP1319070A2 (en) 2000-09-12 2003-06-18 Oregon Health & Science University Mammalian receptor genes and uses
ES2248413T3 (es) 2000-11-14 2006-03-16 F. Hoffmann-La Roche Ag Derivados de 2-fenilaminoimidazolin fenil cetona sustituido como antagonistas de ip.
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
TW200930291A (en) 2002-04-29 2009-07-16 Bayer Cropscience Ag Pesticidal heterocycles
KR100492252B1 (ko) 2002-08-09 2005-05-30 한국화학연구원 이미다졸을 포함하는 이차아민으로 치환된 벤조피란유도체 및 그의 제조방법
MX2007013417A (es) 2005-05-03 2008-01-16 Bayer Cropscience Ag Derivados de heteroarilo y heterociclicos de aminoalquilo sustituidos con pesticidas.
AU2006283104A1 (en) 2005-08-25 2007-03-01 Pharmacopeia, Inc. Imidazole derivatives as functionally selective alpha2C adrenoreceptor agonists
WO2008052907A1 (en) 2006-11-02 2008-05-08 F. Hoffmann-La Roche Ag Substituted 2-imidazoles as modulators of the trace amine associated receptors
JP2010510184A (ja) 2006-11-16 2010-04-02 エフ．ホフマン−ラ ロシュ アーゲー 置換４−イミダゾール類
CN101557810B (zh) 2006-12-13 2012-11-21 弗·哈夫曼-拉罗切有限公司 作为痕量胺相关受体（taar）的配体的新的2-咪唑类

Also Published As

Publication number Publication date
CA2671838A1 (en) 2008-06-26
US20120004230A1 (en) 2012-01-05
JP5175297B2 (ja) 2013-04-03
MX2009006215A (es) 2009-06-22
TWI345467B (en) 2011-07-21
JP2010513373A (ja) 2010-04-30
TW200833327A (en) 2008-08-16
CL2007003653A1 (es) 2008-07-11
CN101578271B (zh) 2013-06-19
KR20090081431A (ko) 2009-07-28
ZA200903841B (en) 2010-03-31
IL198878A0 (en) 2010-02-17
US20100204233A1 (en) 2010-08-12
EP2094668A2 (en) 2009-09-02
WO2008074679A3 (en) 2008-10-09
CN101578271A (zh) 2009-11-11
US20080146523A1 (en) 2008-06-19
US8399463B2 (en) 2013-03-19
WO2008074679A2 (en) 2008-06-26
KR101188992B1 (ko) 2012-10-08
NO20091936L (no) 2009-07-14
BRPI0721291A2 (pt) 2014-03-25
RU2465269C2 (ru) 2012-10-27
AU2007336351A1 (en) 2008-06-26
RU2009122665A (ru) 2011-01-27
PE20081386A1 (es) 2008-09-18

Similar Documents

Publication Publication Date Title
AR064376A1 (es) Imidazoles sustituios como ligandos de taar, un proceso para su obtencion, y su uso en la preparacion de un medicamento para el tratamiento de enfermedades asociadas a la desregulacion de aminas traza.
ES2898315T3 (es) Preparación de nicotina racémica mediante reacción de nicotinato de etilo con n-vinilpirrolidona en presencia de una base de alcoholato y etapas de proceso posteriores
Loev et al. An improved synthesis of carbamates
AU2007266761B2 (en) Process for the production of benzopyran-2-ol derivatives
HK1111999A1 (en) Spiroketal derivative and use thereof as diabetic medicine
HRP960082A2 (en) Process for producing thietanones
HK1113790A1 (en) Selurampanel
PL2428519T3 (pl) Kompozycja do wytwarzania 17-winylo-trifluorometanosulfonianów jako związków pośrednich
WO2008117269A3 (en) Heterotri cyciii c compounds as serotonergic and/or dopaminergic agents and uses thereof
NZ597638A (en) 5-fluoro-2-oxopyrimidine- 1(2h)-carboxylate derivatives
KR20190025991A (ko) 4-알콕시-3-(아실 또는 알킬)옥시피콜린아미드의 제조 방법
CA2665347C (en) Process for the preparation of pleuromutilins
WO2006013049A3 (en) Benzyloxy derivatives as maob inhibitors
ES2715503T3 (es) Un nuevo método de producción de clorhidrato de nebivolol de alta pureza
FR2470770A1 (fr) Nouveaux ethers de b-imidazolylethyle de quinoleine-2 ou 4-methanols, utiles notamment comme antimicrobiens, et leur procede de preparation
CN101781272B (zh) 一种瑞格列奈胺的制备方法及其中间体
US6825353B2 (en) Process for producing quinolonecarboxylic acids and intermediates thereof
AU3590801A (en) One-pot synthesis of alkyl 3-cyclopropylamino-2-(2,4-dibromo-3-(difluoromethoxy)benzoyl -2-propenoate as a useful intermediate for antibacterial quinolone medicaments
AU2009275667A1 (en) Process for the preparation of O-desmethylvenlafaxine
ES2387793T3 (es) Proceso para la preparación de loperamida
KR20010023730A (ko) 입체이성 인돌 화합물, 그 제조방법 및 용도
KR20170016387A (ko) 피페리딘-4-카보티오아미드의 제조
TNSN06066A1 (en) Process for the purification of terbinafine
Coop et al. L-Selectride as a convenient reagent for the selective cleavage of carbamates
EP2855422B1 (en) Synthesis of diamido gellants by using dane salts of amino acids

Legal Events

Date Code Title Description
FB Suspension of granting procedure